Document Detail

Topotecan in the treatment of recurrent small cell lung cancer: an update.
MedLine Citation:
PMID:  15616145     Owner:  NLM     Status:  MEDLINE    
Small cell lung cancer (SCLC) is an aggressive malignancy with a high propensity for early regional and distant metastasis. Response rates to first-line chemotherapy are typically high, but short lived. The outlook for patients with recurrent SCLC is poor. A variety of single- and multi-agent chemotherapy regimens have met with limited success in patients with recurrent SCLC, and survival is generally measured in weeks. Until recently, further chemotherapy was not widely considered appropriate for patients with relapsed SCLC. The choice of chemotherapy at relapse is dependent on many factors, including type of and response to first-line therapy, the treatment-free interval, and the patient's performance status. Intravenous topotecan (Hycamtin; GlaxoSmithKline; Philadelphia, PA) has provided oncologists and patients in many countries with an effective and tolerable therapeutic option for recurrent SCLC. The clinical profile of topotecan was established in several phase II studies and confirmed in a randomized, phase III trial versus cyclophosphamide, doxorubicin (Adriamycin; Bedford Laboratories; Bedford, OH), and vincristine (Oncovin; Eli Lilly and Company; Indianapolis, IN)--CAV. In those studies, topotecan exhibited antitumor activity in both chemosensitive and refractory disease. Further, topotecan therapy is associated with significant symptom palliation in this patient population. Because the toxicity profile of topotecan is predictable, generally manageable, and noncumulative, the agent also has potential utility in patients with a poor prognosis and/or a poor performance status. Alternative dosing regimens (lower dose, weekly) and the introduction of an oral formulation may expand the use of topotecan as a single agent and in combination therapy in the second- and first-line treatment of this disease.
Andrea Ardizzoni
Related Documents :
17057045 - Intrathecal topotecan in adult patients with neoplastic meningitis.
12033195 - Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lun...
12775425 - Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive mu...
20881835 - Second high-dose chemotherapy intensification followed by hematopoietic stem cell trans...
8918405 - Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma pa...
15850065 - Clinical experience with single-agent gemcitabine chemotherapy in patients with non-sma...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  The oncologist     Volume:  9 Suppl 6     ISSN:  1083-7159     ISO Abbreviation:  Oncologist     Publication Date:  2004  
Date Detail:
Created Date:  2004-12-23     Completed Date:  2005-03-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9607837     Medline TA:  Oncologist     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4-13     Citation Subset:  IM    
Medical Oncology, University Hospital, Via Gramsci 14, 43100 Parma, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects,  therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Small Cell / drug therapy*,  secondary*
Lung Neoplasms / drug therapy*,  pathology
Neoplasm Recurrence, Local / drug therapy*
Topotecan / adverse effects,  therapeutic use*
Reg. No./Substance:
0/Antineoplastic Agents; 123948-87-8/Topotecan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Homologs of Drosophila P transposons were mobile in zebrafish but have been domesticated in a common...
Next Document:  Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom...